Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

Cencora reported fiscal Q4 2026 revenue of $88.4 billion, up 5.5% year over year, and fiscal-year revenue of $337.4 billion, up 5.0%. GAAP diluted EPS was $2.71 versus a loss of $1.75 per share in the prior-year quarter; the article text cuts off before giving adjusted EPS or further details.

Analysis

The revenue trend is supportive but not, by itself, a strong signal for distributor earnings: Cencora’s large reported sales base does not establish the profitability of incremental volume. The GAAP EPS swing is also a poor read-through without the prior-year and current-year adjustment bridge; the release excerpt ends before adjusted EPS, guidance, cash flow, or segment detail. Those omissions matter more than the headline growth rate for assessing earnings quality and valuation.

Over the next few days, the key risk is an initial positive reaction to the EPS comparison outrunning what recurring earnings support. Over 1–3 months, compare Cencora’s adjusted EPS outlook and cash conversion with McKesson and Cardinal Health; sustained relative execution would be more meaningful than revenue growth alone. Over 6–18 months, the structural question is whether mix and operating execution can translate distribution scale into durable per-share earnings, rather than merely higher pass-through sales. A weaker outlook, declining cash conversion, or a narrowing relative-performance advantage would falsify a constructive view. The excerpt supports watchful optimism, not a high-conviction directional trade.

Key Decisions for Investors

• Do not trade the GAAP EPS reversal in isolation. Verify the full adjusted EPS reconciliation, FY2027 guidance, segment performance, and operating cash flow before treating the quarter as an earnings inflection.
• Monitor COR against McKesson and Cardinal Health over the next 1–3 months; favor relative exposure only if adjusted earnings outlook and cash conversion confirm an advantage, not merely faster reported sales.
• If the stock rallies sharply on the headline before the complete release is assessed, avoid chasing; a reversal in guidance or weak cash conversion would be a near-term reason to reduce exposure.
• No immediate options or pair trade is warranted from this excerpt alone; reassess once the missing earnings and guidance details are available.